Daily supplements may cut heart risks for diabetes patients
NCT ID NCT06351566
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested whether taking daily vitamin D3 and prebiotics (inulin) for six months could improve heart health markers in 190 adults with type 2 diabetes. Researchers measured blood sugar control, cholesterol, and gut bacteria changes. The goal is to find simple dietary ways to lower cardiovascular risk in this population.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- vitamin D3 (cholecalciferol) and prebiotics (inulin)
- What this could lead to
- If it works, this could point toward a simple dietary supplement strategy to help manage heart disease risk in people with type 2 diabetes.
- What could go wrong
- This is a small, completed study, so results may not apply to everyone. Supplements are not a substitute for standard diabetes care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
190 people
The number who actually took part.
- Started
-
Apr 2024
- Finished
-
Aug 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
35 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Type 2 diabetes (meeting any of the following criteria): Physician-diagnosed type 2 diabetes, use of oral hypoglycemic medication or insulin, fasting blood glucose ≥ 7.0 mmol/L, HbA1c ≥ 6.5% (48 nmol/L), 2-hour plasma glucose (2hPG) ≥ 11.1 mmol/L. 2. Men aged 35-70 years or women aged 35-70 years. 3. Convenient access to study centers. 4. Written informed consent obtained before any trial-related activities. Exclusion Criteria: 1. History of macrovascular diseases (including Coronary heart disease, myocardial infarction, heart failure, stroke, transient ischemic attack, peripheral vascular disease, post coronary artery bypass surgery). 2. History of diabetic microvascular complications (including diabetic nephropathy, diabetic retinopathy, or diabetic neuropathy). 3. History of other cardiovascular diseases (including aortic stenosis, transient ischemic attack, angina pectoris, cardiac arrest, complex ventricular arrhythmias, or surgery of cardiovascular diseases). 4. History of cancer, excluding non-melanoma skin cancer or cancers with a good prognosis (such as stage 1 cervical cancer). 5. Severe liver disease (such as cirrhosis), severe kidney disease (such as renal failure or requiring dialysis), or severe gastrointestinal disease (such as a history of bowel obstruction). 6. Kidney stones, hypercalcemia, parathyroid hormone abnormality. 7. Sarcoidosis or other granulomatous diseases, such as active chronic pulmonary tuberculosis or Wegener's granulomatosis. 8. Any mental disorders, such as schizophrenia, other mental disorders, or bipolar disorder. 9. Individuals with infectious diseases such as HIV/AIDS, viral hepatitis. 10. Individuals requiring long-term hospitalization or those with other serious illnesses requiring immediate hospital treatment. 11. In the past 3 months, those who have taken any vitamin D supplements exceeding 400 IU/day, calcium supplements exceeding 600 mg/day, prebiotics exceeding 2 g/day, or probiotics exceeding 10\^8 colony forming units/day. 12. History of allergy or intolerance to vitamin D, prebiotics, or starch. 13. Individuals with unhealthy habits: heavy alcohol consumption (\>80 grams/day for males, \>40 grams/day for females) or smoking (\>40 cigarettes/day). 14. Individuals with cognitive impairment, inability to communicate properly, inability to take care of themselves, or those with mobility issues. 15. Those having participated in other clinical trials or studies in the past 3 months. 16. Those who are intent to become pregnant within the next two years, are currently pregnant, or breastfeeding. 17. Individuals with abnormal laboratory tests and clinical manifestations who are judged by the researcher to be unsuitable for participation.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diabetes mellitus type 2 are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bao'an Center Hosipital of Shenzhen
Shenzhen, Guangdong, China
-
School of Public Health, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a nurse and a neighbor help tame chronic disease?
- Which SGLT2 inhibitor wins? trial pits empagliflozin against dapagliflozin
- Can a vegan diet shield police officers from heart disease?
- Can a health coach in your patient portal help you lose weight?
- Common antibiotic may boost diabetes control
- Can continuous glucose monitors safely tighten hospital blood sugar control?